Mechanism of Action
Antimicrobial Membrane Disruption
LL-37 adopts an amphipathic alpha-helical structure in lipid environments. It inserts into bacterial membranes through a toroidal pore mechanism, disrupting membrane integrity and leading to cell death. The peptide is active against a broad spectrum including MRSA, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and HSV. Activity is reduced at physiological salt concentrations (140 mM NaCl), requiring higher concentrations for in vivo efficacy than in vitro MIC values suggest.
Immunomodulatory Signaling
LL-37 activates formyl peptide receptor-like 1 (FPRL1/FPR2) on immune cells, promoting chemotaxis of neutrophils, monocytes, and T cells. It neutralizes LPS (endotoxin), reducing TLR4-mediated inflammatory cytokine storm. LL-37 also activates P2X7 receptors, EGFR, and various intracellular signaling pathways to promote wound healing, angiogenesis, and epithelial repair. These receptor-mediated immunomodulatory functions may be as important as direct antimicrobial activity in host defense.
Research Summary
Wound Healing
Clinical EvidenceLL-37 promotes keratinocyte and fibroblast migration and proliferation via EGFR transactivation. Topical LL-37 accelerates wound closure in diabetic mouse models and venous leg ulcer biopsies show reduced LL-37 expression. Phase II trials of topical LL-37 for chronic venous leg ulcers showed improved healing compared to placebo, supporting clinical development.
Lung Infections
Clinical/PreclinicalInhaled LL-37 analogs have been tested in cystic fibrosis (CF) lung infection models. CF patients have reduced functional LL-37 due to salt inhibition in hypersecretory airway fluid. Aerosolized LL-37 or its analogs improve bacterial clearance in murine P. aeruginosa chronic lung infection models. Phase I inhalation safety studies have been conducted.
Cancer Research
PreclinicalLL-37 has dual cancer roles: it promotes angiogenesis via VEGF receptor activation (potentially tumor-promoting) but directly kills several cancer cell lines via membrane disruption. Context-dependent pro- and anti-tumor effects have been reported. Anti-tumor LL-37 activity is being explored in melanoma and ovarian cancer models.
Calculate your Cathelicidin (LL-37) dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial MIC (in vitro) | 1-32 ug/mL | Single MIC determination | In vitro |
| Wound healing (topical) | 50-100 ug/cm2 | Daily application | Topical cream/gel |
| Lung infection (preclinical) | 0.5-2 mg/mL inhaled | Once or twice daily | Aerosol inhalation |
Clinical development is ongoing for topical wound and inhaled respiratory indications. No systemic IV dosing established for humans.
Interactions
Safety Profile
Topical LL-37 in Phase I/II trials shows good local tolerability with minimal systemic absorption and no serious adverse events. At high concentrations, LL-37 is cytotoxic to mammalian cells, limiting systemic administration. Physiological LL-37 deficiency (e.g., vitamin D deficiency) increases infection susceptibility. Elevated LL-37 is associated with inflammatory skin conditions (psoriasis, rosacea) where it acts as an endogenous TLR7/TLR9 activator via self-DNA complexes. LL-37 is not WADA-listed.
References
- [1]Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75(1):39-48.
- [2]Wang G, et al. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem. 2008;283(47):32637-32643.
- [3]Heilborn JD, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379-389.